ライフサイエンスコーパス: PPAR

1 PPAR agonists have well-documented anti-inflammatory and

2 PPAR response element (PPRE) activity was measured in PP

3 PPAR-alpha activation in the enterocyte on HDL and chylo

4 PPAR-beta/delta activation exacerbates, and its inhibiti

5 PPAR-beta/delta may regulate preretinal NV through a pro

6 PPAR-delta activation also reduced HTT-induced neurotoxi

7 PPAR-delta overexpression in colonic epithelial cells pr

8 PPAR-gamma agonists modulate NF-kappaB-dependent inflamm

9 PPAR-gamma agonists, like pioglitazone, appear antiprote

10 PPAR-gamma ligands abrogated these effects.

11 e (P = 0.026), and 2.25 +/- 0.25 in 15-LOX-1-PPAR-delta-Gut mice (P = 0.0006).

12 ession in colonic epithelial cells (15-LOX-1-PPAR-delta-Gut mice) suppressed these effects: the numbe

13 is required for the induction of PGC-1alpha/PPAR-alpha target genes and oxidative metabolism in resp

14 ome proliferator-activated receptor gamma 2 (PPAR-gamma2), a potent lipogenic transcription factor, i

15 Surprisingly, GW0742 behaved as a PPAR agonist and antagonist, activating transcription at

16 ewal potential of these organoid bodies in a PPAR-delta-dependent manner.

17 Even more effective was probucol, a PPAR-activating anti-lipid drug that we show also inhibi

18 tazone, in a manner inhibited by T0070907, a PPAR-gamma antagonist that also inhibited the ACEA effec

19 ng dietary-induced liver fibrosis, we used a PPAR-alpha mutant lacking its DNA-binding-dependent acti

20 t induces Angptl4 and FABP4 expression via a PPAR-dependent pathway.

21 We further demonstrate that treatment with a PPAR-alpha agonist, bezafibrate, is able to reverse the

22 When combined with a PPAR-gammainhibitor GW9662, the effect of DAPA on ZAG wa

23 rat liver caused by dietary treatment with a PPAR-pan (PPAR-alpha, -gamma, and -delta) agonist were p

24 PPAR-alpha-dependent metabolism and abnormal PPAR-gamma pathway in beating embryoid bodies (EBs) with

25 IL-10R blockage abolished PPAR-gamma-mediated inhibition of MyD88 expression.

26 Fatty acids bind and activate PPAR-alpha; therefore, it has been presumed that fatty a

27 n factor known to interact with and activate PPAR-gamma and NF-kappaB, is suppressed in the glomerula

28 Treatments that activate PPAR-alpha, PPAR-gamma, and PPAR-delta alone or in combi

29 opment of therapeutic strategies to activate PPAR-alpha as well as other PPARs may lead to new therap

30 uclear factor 4 alpha (HNF-4alpha)-activated PPAR-gamma2 gene expression by direct inhibition of HNF-

31 Notably, HFD- and agonist-activated PPAR-delta signalling endow organoid-initiating capacity

32 Therefore, microbiota-activated PPAR-gamma signaling is a homeostatic pathway that preve

33 Pharmacologically activated PPAR-alpha inhibited hepatic inflammatory responses and

34 lpha-type peroxisome proliferator-activated (PPAR-alpha) receptors; (2) shifted nicotine self-adminis

35 (Tricor), a pan-PPAR agonist that activates PPAR-alpha as well as other PPARs.

36 activated by PPAR-alpha agonists, additional PPAR-alpha is recruited to GR-adjacent sites and presuma

37 l kinase, which are induced by high affinity PPAR agonists.

38 ferator-activated receptor-gamma and -alpha (PPAR-gamma/-alpha) in the NTS and NG in HFD rats were ma

39 isome proliferator-activated receptor alpha (PPAR) target genes, Cpt1alpha, Pgc1alpha, and Ucp1, and

40 isome proliferator-activated receptor alpha (PPAR-alpha) by the PPAR-alpha agonists GW7647 and fenofi

41 isome proliferator-activated receptor alpha (PPAR-alpha) stimulation.

42 isome proliferator-activated receptor alpha (PPAR-alpha).

43 FAS, PPAR-alpha, PPAR-gamma, and CB1-R were markedly altered in WT-FF.

44 Treatments that activate PPAR-alpha, PPAR-gamma, and PPAR-delta alone or in combination have

45 tor-activated receptors (PPARs), PPAR-alpha, PPAR-gamma, and PPAR-delta.

46 -6, and FIV RNA detection in brain, although PPAR-gamma in glia was increased compared with PBS-treat

47 naling on SIRT1 activity, and PGC-1alpha and PPAR-alpha target gene expression independent of changes

48 naling (4.47), insulin signaling (3.81), and PPAR pathways (3.75), and downregulated pathways involve

49 phosphorylation, IL-6 promoter activity, and PPAR-delta mRNA and protein expression.

50 ferator-activated receptor (PPAR)-alpha, and PPAR-gamma.

51 lism that were associated with IL6, AMPK and PPAR signal pathways.

52 ptor gamma in luciferase reporter assay, and PPAR-gamma selective antagonist completely inhibited MDS

53 tory network consisting of GATA3, FOXA1, and PPAR drive luminal cell fate.

54 ts that activate PPAR-alpha, PPAR-gamma, and PPAR-delta alone or in combination have the potential to

55 ceptors (PPARs), PPAR-alpha, PPAR-gamma, and PPAR-delta.

56 tor-activated receptor delta (PPARdelta) and PPAR gamma coactivator 1 alpha (PGC1alpha), key transcri

57 Agonists of nuclear receptors LXR:RXR and PPAR:RXR act to ameliorate AD-related cognitive impairme

58 responsible for the linkage between SHP and PPAR-gamma2 using hepatic RNAs isolated from SHP(-/-) an

59 tiation through direct regulation of ST2 and PPAR-gamma expression.

60 vascular endothelium, with decreased TJ and PPAR-gamma expression, and increased pulmonary macrophag

61 hways, including LPS, members of the TLR and PPAR families, NF-kappaB, and TNF-related weak inducer o

62 to those of the human, ERs, AR, GR, ERRs and PPARs were more variable with similarities of 60%-100% a

63 derived from ATGL-catalyzed lipolysis act as PPAR-alpha ligands.

64 besogen by PPARgamma transactivation assays, PPAR-driven luciferase induction in vivo, PPARgamma bind

65 its protective effects are mediated by both PPAR-alpha-dependent and -independent mechanisms.

66 ly, and 4) associated with reduction of both PPAR-gamma and catalase activity, which are reversed by

67 uorescence microscopy to determine that both PPAR mRNA and protein are expressed ubiquitously through

68 y chromatin sites with GR; when activated by PPAR-alpha agonists, additional PPAR-alpha is recruited

69 nteractions due to upregulation of CYP2C8 by PPAR activators.

70 paB promoter activity, which was reversed by PPAR-gamma agonist.

71 driven growth of urothelium is reversible by PPAR inhibition, supporting PPARs as targetable drivers

72 ceptor-gamma (PPAR-gamma) ligand that causes PPAR-gamma dissociation from Smad2/3, allowing Smad2/3 a

73 trol and corticosteroid-treated BFU-E cells, PPAR-alpha co-occupies many chromatin sites with GR; whe

74 direct PPARalpha target gene via a conserved PPAR response element located 1200 base pairs upstream o

75 P-dependent regulatory cascade that controls PPAR-gamma2 gene expression, thereby regulating hepatic

76 sion of wild-type or a DNA-binding-deficient PPAR-alpha in acute and chronic models of inflammation w

77 isome proliferator-activated receptor delta (PPAR-delta) interacts with HTT and that mutant HTT repre

78 isome proliferator-activated receptor delta (PPAR-delta) signature in intestinal stem cells and proge

79 isome proliferator-activated receptor-delta (PPAR-delta), which is implicated in bile acid homoeostas

80 Dissociated PPAR-alpha agonists, selectively modulating PPAR-alpha t

81 The dual PPAR-alpha/delta agonist, GFT505, is a promising liver-t

82 y pretreatment with an antagonist for either PPAR-alpha (MK886) or cannabinoid CB1 receptors (rimonab

83 iating capacity to progenitors, and enforced PPAR-delta signalling permits these progenitors to form

84 drazine (PHZ)-induced stress erythropoiesis, PPAR-alpha agonists facilitate recovery of wild-type but

85 ), a coactivator of the transcription factor PPAR-gamma that controls mitochondrial biogenesis and fu

86 elopment depends on the transcription factor PPAR-gamma; however, the environmental cues required for

87 FAS, PPAR-alpha, PPAR-gamma, and CB1-R were markedly altered

88 14,643, besides being valued as agonists for PPAR, also inhibit hAR.

89 a To determine the mechanism responsible for PPAR-mediated upregulation, we prepared reporter plasmid

90 us validating the oxazolidinone template for PPAR activity.

91 inding assays, we have mapped the functional PPAR-responsive element to a proximal region from -135 t

92 some proliferation-activated receptor gamma (PPAR) agonist medications, such as antidiabetic glitazon

93 isome-proliferator-activated receptor gamma (PPAR-gamma) and downstream target genes were down-regula

94 isome proliferator-activated receptor gamma (PPAR-gamma) and glucose transporter 1 (GLUT-1) levels in

95 isome proliferator-activated receptor gamma (PPAR-gamma) expression.

96 isome proliferator-activated receptor gamma (PPAR-gamma) is a downstream target of sildenafil in the

97 isome proliferator-activated receptor gamma (PPAR-gamma), which is suppressed by HIV-1 replication.

98 isome proliferator-activated receptor gamma (PPAR-gamma).

99 isome proliferator-activated receptor-gamma (PPAR-gamma) agonist, troglitazone, in a manner inhibited

100 isome proliferator-activated receptor-gamma (PPAR-gamma) and sterol regulatory element binding protei

101 isome proliferator-activated receptor-gamma (PPAR-gamma) ligand that causes PPAR-gamma dissociation f

102 isome proliferator-activated receptor-gamma (PPAR-gamma) systems and propose that these systems may r

103 isome proliferator-activated receptor-gamma (PPAR-gamma), may counterregulate inflammation in a tissu

104 isome proliferator-activated receptor-gamma (PPAR-gamma), which is induced by exposure to granulocyte

105 isome proliferator-activated receptor-gamma (PPAR-gamma).

106 determined that the Adam10 promoter harbors PPAR response elements; that knockdown of PPARalpha, but

107 TCGA raised the possibility that hyperactive PPAR signaling, either due to PPAR gamma gene amplificat

108 8 in wild-type littermates, 6.67 +/- 0.83 in PPAR-delta-Gut mice (P = 0.026), and 2.25 +/- 0.25 in 15

109 Our results fill critical gaps in PPAR distribution and define novel cell type specificity

110 eated with pioglitazone showed reductions in PPAR-gamma (Ser-273) phosphorylation.

111 No such effect was seen in PPAR-alpha-deficient mice.

112 eraction with the terminal tyrosine found in PPARs.

113 ression of lipid metabolism genes, including PPAR-gamma, by directly methylating their promoters.

114 Increased PPAR-delta transactivation ameliorated mitochondrial dys

115 Indeed, PPAR induces the expression of genes involved in lipid s

116 Microbiota-induced PPAR-gamma signaling also limits the luminal bioavailabi

117 on of antisteatotic versus anti-inflammatory PPAR-alpha activities in counteracting dietary-induced l

118 ceptors (PPARs), which led us to investigate PPAR agonists for activity at the cannabinoid receptors.

119 sults identify a signaling pathway involving PPAR-gamma, ERK, and MUC1 for TNF-alpha secretion induce

120 e antidiabetic drug rosiglitazone, all known PPAR activators.

121 These findings highlight how diet-modulated PPAR-delta activation alters not only the function of in

122 PPAR-alpha agonists, selectively modulating PPAR-alpha transrepression activity, could thus be an op

123 Expression of dominant-negative PPAR-delta in the central nervous system of mice was suf

124 Expression of dominant-negative PPAR-delta specifically in the striatum of medium spiny

125 In conclusion, our results describe a new PPAR ligand, modulating lipid and glucose metabolism wit

126 We highlight the potential of new PPAR ligands with improved efficacy and safety profiles

127 By co-activating normal PPAR-alpha-dependent metabolism and abnormal PPAR-gamma

128 droplet-associated (Hilpda/Hig2) as a novel PPAR target gene and demonstrate its involvement in hepa

129 together, our data uncover HILPDA as a novel PPAR target that raises hepatic triglyceride storage via

130 beta-catenin content and normalized nuclear PPAR-gamma in Ob-MSCs.

131 PRE (at nt -769) was essential for obtaining PPAR-mediated transcriptional activation.

132 ide synthase, was elevated in the absence of PPAR-gamma signaling.

133 is study demonstrates that the activation of PPAR-alpha action via fenofibrate leads to neuroprotecti

134 em cells), and pharmacological activation of PPAR-delta recapitulates the effects of a HFD on these c

135 se models of HD, pharmacologic activation of PPAR-delta using the agonist KD3010 improved motor funct

136 tion and suggest that impaired activation of PPAR-gamma contributes to the chronic inflammatory state

137 ts suggest that CBD may induce activation of PPAR-gamma in mast cells leading to secretion of G-CSF a

138 Activation of PPAR-gamma prevented HIV-1-induced claudin-5 down-regula

139 on of ZAG in the liver via the activation of PPAR-gamma.

140 The transrepression activity of PPAR-alpha on chronic liver inflammation is sufficient t

141 Palmitoylethanolamide is an agonist of PPAR-alpha and an important regulator of pain and innate

142 nous administration of synthetic agonists of PPAR-gamma (pioglitazone and rosiglitazone) up-regulates

143 a through cGMP- and PKG-dependent binding of PPAR-gamma to the TRPC6 promoter, which inhibits TRPC6 p

144 rotein response and suggest that blockade of PPAR-gamma (Ser-273) phosphorylation may prevent type 1

145 However, the distribution of PPAR mRNA and protein in brain regions associated with t

146 rough mechanisms involving downregulation of PPAR-gamma and increased activation of NF-kappaB.

147 m and IP is associated with dysregulation of PPAR-gamma.

148 we explored the anti-inflammatory effect of PPAR-gamma stimulation in vivo in cystic fibrosis transm

149 mmatory processes, whereas the expression of PPAR and insulin target gene transcripts was increased.

150 This study aims to explore expression of PPAR-gamma and NF-kappaB in placentas of women with peri

151 roups and analyzed to quantify expression of PPAR-gamma and NF-kappaB using real-time polymerase chai

152 R-defective biliary epithelium expression of PPAR-gamma is increased but that this does not result in

153 Expression of PPAR-gamma was downregulated in patients with preeclamps

154 These studies unravel a novel function of PPAR-gamma in controlling biliary epithelium inflammatio

155 Pharmacologic inhibition of PPAR-beta/delta may provide a rational basis for therape

156 Thus, inhibition of PPAR-gamma and GLUT-1 by E. coli K1 is a novel pathogeni

157 Importantly, inhibition of PPAR-gamma partially prevents the increase in tumorigene

158 us carcinomas are sensitive to inhibition of PPAR-gamma.

159 trating T cells showed a progressive loss of PPAR-gamma coactivator 1alpha (PGC1alpha), which program

160 Thus, regulation of PPAR-gamma can be a therapeutic approach against HIV-1-i

161 onary barrier integrity), down-regulation of PPAR-gamma transcription, and expression in lung tissues

162 s an important mediator of the regulation of PPAR-gamma2 transcription by SHP.

163 T demonstrated consistent down-regulation of PPAR-signaling under CR and MR, whereas muscle was large

164 This miR-27b-mediated repression of PPAR-alpha signaling represents a novel mechanism of HCV

165 Our discovery of the role of PPAR-alpha agonists in stimulating self-renewal of early

166 Stimulation of PPAR-gamma in vivo (rosiglitazone) significantly attenua

167 Identification of 15-LOX-1 suppression of PPAR-delta to inhibit IL-6/STAT3 signaling-driven CAC tu

168 The suppression of PPAR-gamma and GLUT-1 by the bacteria in the brain micro

169 e after CSE induction through suppression of PPAR-gamma or ERK inhibited TACE activity and TNF-alpha

170 ingitis, and pharmacological upregulation of PPAR-gamma and GLUT-1 levels may provide novel therapeut

171 Moreover, the cell type specificity of PPARs in mouse and human brain tissue has yet to be inve

172 down or application of antagonists of PKG or PPAR-gamma enhanced TRPC6 expression in podocytes and co

173 In mouse urothelial organoids, PPAR agonism is sufficient to drive growth-factor-indepe

174 gies to activate PPAR-alpha as well as other PPARs may lead to new therapeutic agents to slow or halt

175 t that activates PPAR-alpha as well as other PPARs.

176 caused by dietary treatment with a PPAR-pan (PPAR-alpha, -gamma, and -delta) agonist were profiled by

177 the efficacy of fenofibrate (Tricor), a pan-PPAR agonist that activates PPAR-alpha as well as other

178 hat the administration of bezafibrate, a pan-PPAR agonist, increases the expression of PGC-1alpha and

179 me proliferator-activated receptors (PPARs), PPAR-alpha, PPAR-gamma, and PPAR-delta.

180 ediated effects of the hormone by preventing PPAR-gamma inhibition by leptin, with subsequent increas

181 abinoid receptors in addition to its primary PPAR target.

182 However, prolonged PPAR treatment in animal models has led to adverse side

183 presses HSPs through factors other than RAR, PPAR or NFkappaB despite the presence of these factors'

184 Rats receiving PPAR-gamma antagonists displayed proteinuria and increas

185 creases the activity of the nuclear receptor PPAR-alpha, a PGC-1alpha binding partner, to promote fat

186 The nuclear receptor PPAR-beta/delta (PPARD) has essential roles in fatty aci

187 nsitizers that activate the nuclear receptor PPAR-gamma and have been shown to partially ameliorate a

188 h a mechanism involving the nuclear receptor PPAR-gamma.

189 peroxisome proliferator-activated receptor (PPAR) alpha [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio

190 peroxisome proliferator-activated receptor (PPAR) alpha and gamma To determine the mechanism respons

191 peroxisome proliferator-activated receptor (PPAR) alpha ligand that has antiinflammatory actions and

192 peroxisome proliferator-activated receptor (PPAR) alpha ligand that has been widely used as a lipid-

193 peroxisome proliferator-activated receptor (PPAR) alpha, alone and in conjunction with all-trans-ret

194 peroxisome proliferator-activated receptor (PPAR) alpha.

195 peroxisome proliferator-activated receptor (PPAR) beta/delta (ST247) and PPARgamma (GW9662).

196 peroxisome proliferator-activated receptor (PPAR) beta/delta deficiency in hepatic FGF21 regulation.

197 peroxisome proliferator-activated receptor (PPAR) beta/delta, a regulator of metabolism, fibrosis, a

198 peroxisome proliferator-activated receptor (PPAR) family comprises three subtypes: PPARalpha, PPARga

199 peroxisome proliferative-activated receptor (PPAR) family of transcription factors and are critical f

200 peroxisome proliferator activated receptor (PPAR) family, liver X receptors (LXRs), and farnesoid X

201 peroxisome proliferator-activated receptor (PPAR) gamma agonism reversed TNFalpha-induced insulin re

202 Peroxisome proliferator-activated receptor (PPAR) gamma agonists, including pioglitazone, approved f

203 peroxisome proliferator-activated receptor (PPAR) gamma target genes beyond Glut4.

204 peroxisome proliferator-activated receptor (PPAR) gamma, CCAAT/enhancer binding protein (CEBP) alpha

205 peroxisome proliferator-activated receptor (PPAR) gamma, which regulates its activity in the opposit

206 peroxisome proliferator-activated receptor (PPAR) is a transcription factor whose expression is indu

207 Peroxisome Proliferator Activated Receptor (PPAR) pathway would be related to brain development.

208 peroxisome proliferator-activated receptor (PPAR), respectively, thereby contributing to healthy lon

209 peroxisome proliferator-activated receptor (PPAR)-alpha agonism can efficiently oppose these symptom

210 peroxisome proliferator-activated receptor (PPAR)-alpha and angiopoietin-like protein 3 (ANGPTL3), k

211 peroxisome proliferator-activated receptor (PPAR)-alpha and its downstream targets within 6-8 hours.

212 peroxisome proliferator-activated receptor (PPAR)-alpha signaling and catabolism of fatty acids (FAs

213 peroxisome proliferator-activated receptor (PPAR)-alpha, and PPAR-gamma.

214 peroxisome proliferator-activated receptor (PPAR)-alpha.

215 Peroxisome proliferator-activated receptor (PPAR)-delta, a lipid nuclear receptor, up-regulates IL-6

216 Peroxisome proliferator-activated receptor (PPAR)-gamma activation leads to suppression of productio

217 peroxisome proliferator-activated receptor (PPAR)-gamma coactivator (PGC)-1beta, were downregulated

218 peroxisome proliferator-activated receptor (PPAR)-gamma coactivator-1alpha (PGC-1alpha), a transcrip

219 Peroxisome proliferator-activated receptor (PPAR)-gamma is a nuclear receptor with pleiotropic effec

220 Peroxisome proliferator-activated receptor (PPAR)-gamma is expressed in lung tissues and regulates i

221 peroxisome proliferator-activated receptor (PPAR)-gamma ligands have been focused on agonists.

222 peroxisome proliferator-activated receptor (PPAR)-gamma mediates CD36 expression.

223 peroxisome proliferator-activated receptor (PPAR)-gamma protein; P < 0.05) compared with NW-MSCs.

224 peroxisome proliferator-activated receptor (PPAR)-gamma proteins.

225 peroxisome proliferator-activated receptor (PPAR)-gamma, while rendered generally unresponsive by a

226 peroxisome proliferator-activated receptor (PPAR)alpha and under normal conditions accounts for 70%

227 peroxisome proliferator-activated receptor (PPAR)beta/delta ligand.

228 Peroxisome proliferator-activated receptor (PPAR)gamma activation, through rosiglitazone treatment,

229 peroxisome proliferator-activated receptor (PPAR)gamma and via PPAR-independent mechanisms, but whet

230 peroxisome proliferator-activated receptor (PPAR)gamma.

231 peroxisome proliferator-activated receptor [PPAR]gamma-induced angiopoietin-related protein) is a mu

232 peroxisome-proliferator-activated receptors (PPAR), and NFkappaB.

233 peroxisome proliferator-activated receptors (PPARs) and is the receptor for the thiazolidinedione cla

234 Peroxisome proliferator-activated receptors (PPARs) are ligand-dependent transcription factors regula

235 Peroxisome proliferator-activated receptors (PPARs) are nuclear hormone receptors that act as ligand-

236 peroxisome proliferator activated receptors (PPARs) chiral ligands have been designed following the a

237 Peroxisome proliferator-activated receptors (PPARs) play major roles in the regulation of hepatic lip

238 Peroxisome proliferator-activated receptors (PPARs) regulate both inflammatory and multiple other pat

239 Peroxisome proliferator-activated receptors (PPARs) regulate energy metabolism and hence are therapeu

240 peroxisome proliferator-activated receptors (PPARs), has been generally used to treat hyperlipidemia

241 peroxisome proliferator-activated receptors (PPARs), PPAR-alpha, PPAR-gamma, and PPAR-delta.

242 peroxisome proliferator-activated receptors (PPARs), we investigated the effects of a PPARgamma antag

243 peroxisome proliferator-activated receptors (PPARs), which led us to investigate PPAR agonists for ac

244 peroxisome proliferator-activated receptors (PPARs).

245 Peroxisome Proliferator-Activated Receptors (PPARs).

246 rs to terminate inflammation, down-regulates PPAR-delta.

247 pioglitazone and rosiglitazone) up-regulates PPAR-gamma-dependent genes, while inhibiting the activat

248 racts with HTT and that mutant HTT represses PPAR-delta-mediated transactivation.

249 iptional activation of lipogenesis, FXR-RXR, PPAR-alpha mediated lipid oxidation and oxidative stress

250 cer/promoter activity in the context of RXRA/PPAR heterodimers in human bladder cancer cells.

251 Pretreatment with partial or selective PPAR-gamma agonists ameliorate the pathological outcomes

252 Chromatin immunoprecipitation showed PPAR-gamma binding to the TRPC6 promoter.

253 GM-CSF and intact GM-CSF receptor signaling, PPAR-gamma was not sufficiently upregulated in developin

254 drugs thiazolidinediones (TZDs) are specific PPAR-gamma agonists.

255 e TRPC6 expression, as did podocyte-specific PPAR-gamma knockout mice, which were more sensitive to a

256 ic models of inflammation were used to study PPAR-alpha's anti-inflammatory versus metabolic activiti

257 This suggests PPAR gamma pathways may be a fruitful drug target in PD.

258 is reversible by PPAR inhibition, supporting PPARs as targetable drivers of bladder cancer.

259 lecular mechanisms, as well as the synthetic PPAR ligands that are used in the clinic or under develo

260 or cells suggests that the clinically tested PPAR-alpha agonists we used may improve the efficacy of

261 Our results demonstrate that PPAR-gamma activation directly improves beta cell functi

262 ed from individuals with HD, indicating that PPAR-delta activation may be beneficial in HD and relate

263 signature, which raises the possibility that PPAR agonists may be targeting neurons rather than glia

264 Here, we show that PPAR also binds to enhancers already active in preadipoc

265 We also show that PPAR-alpha alleviates anaemia in a mouse model of chroni

266 Recent evidence suggests that PPAR agonists are attractive therapeutic agents for trea

267 We found that PPARs have unique cell type specificities that are consi

268 The PPAR agonists also activated a 1-kb reporter containing

269 The PPAR-alpha agonist fenofibrate exhibited submicromolar a

270 they share anti-inflammatory activities, the PPAR isotypes distinguish themselves by differential act

271 activated receptor alpha (PPAR-alpha) by the PPAR-alpha agonists GW7647 and fenofibrate synergizes wi

272 g-induced reinstatement were reversed by the PPAR-alpha antagonist, MK886.

273 Activation of the PPAR (peroxisome proliferator-activated receptor)-fatty

274 entary and distinct metabolic effects of the PPAR isotypes together with the underlying cellular and

275 eceptor alpha (PPARalpha) is a member of the PPAR nuclear hormone receptor superfamily, which can be

276 be partly due to increased expression of the PPAR-gamma co-activator 1-alpha.

277 asculature and the modulatory effects of the PPAR-gamma ligands.

278 lpha homodimer is different from that of the PPAR-gamma-RXR-alpha heterodimer, even when both NR comp

279 eptor alpha, PPARalpha, and PGC1alpha on the PPAR-binding site on the Tfeb promoter as well.

280 RA substitution allosterically regulates the PPAR AF2 domain via an aromatic interaction with the ter

281 lved in FA metabolism through binding to the PPAR response element, called direct repeat 1 (DR1).

282 HRMECs were treated with the PPAR-beta/delta agonist GW0742 and the antagonist GSK066

283 Treatment with the PPAR-gamma agonist rosiglitazone reversed the phenotype.

284 Although agonists of all three PPARs could activate SULT1C3 transcription, RNA interfer

285 hibits TRPC6 expression in podocytes through PPAR-gamma-dependent mechanisms, thereby counteracting p

286 Thus, PPAR utilizes both broadly active and cell type-specific

287 de an alternate mechanism that links ATGL to PPAR-alpha signaling.

288 at hyperactive PPAR signaling, either due to PPAR gamma gene amplification or RXRA hot-spot mutation

289 significant upregulation of genes related to PPAR-mediated lipid metabolism and downregulation of gen

290 ent of Ischemic Heart Failure (STICH) trial, PPAR-2 trial and Heart Failure Revascularisation Trial h

291 rator-activated receptor (PPAR)gamma and via PPAR-independent mechanisms, but whether they might amel

292 ociated with fatty acid/lipid metabolism via PPAR signalling pathway.

293 atty acids in MC3T3 cells increased in vitro PPAR-gamma activity and inhibited beta-catenin activity.

294 uce ACSL1 expression in macrophages, whereas PPAR agonists do not.

295 expression of GATA3 and FOXA1 cooperate with PPAR activation to drive transdifferentiation of a basal

296 o-PGE2 signaling cascade that interacts with PPAR-gamma, Smad2/3, and TAP63.

297 Incubation of macrophages with PPAR-delta agonists was shown to inhibit foam cell forma

298 Treatment with PPAR agonists can reduce the burden of atherogenic postp

299 inal angiogenesis and known to interact with PPARs or PPARGC1A.

300 of fibroblasts with ciprofibrate or WY14643, PPAR-alpha activators, led to peroxisome proliferation a